Receiving regulatory clearance to proceed with a clinical trial is a critical step for biotech companies, often leading to positive investor sentiment. This approval indicates progress in Oncolytics Biotech's research and development efforts, potentially enhancing its market position and investor interest. The focus on a significant health issue like pancreatic cancer, combined with the innovative approach of using Pelareorep in combination therapy, could lead to increased visibility and interest in the company's stock in the short term.